← Back to Search

Cannabinoid

CBD for Traumatic Brain Injury

Phase 2
Recruiting
Led By Kent Hutchison, PhD
Research Sponsored by University of Colorado, Denver
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 0 to week 6, week 0 to week 12

Summary

This trial will assess if CBD can improve cognition & symptoms related to traumatic brain injury in people. Subjects will be randomly assigned a condition for 12 weeks.

Who is the study for?
This trial is for adults aged 18-60 with mild to moderate traumatic brain injury (TBI) who have been evaluated in a hospital setting. Participants should not be involved in other TBI treatment studies, must have stable treatments for four weeks prior, and cannot change these during the study. Exclusions include severe mental illness, unstable medical conditions, high liver enzymes, current heavy cannabis or CBD use, certain neurological disorders, substance abuse issues, and pregnancy.
What is being tested?
The study tests two forms of cannabinoids (fsCBD and bsCBD) against a placebo to see if they can improve cognition and symptoms related to TBI. Participants are randomly assigned to one of these options for a duration of 12 weeks in this double-blind trial where neither the researchers nor participants know who receives the actual drug or placebo.
What are the potential side effects?
While specific side effects are not listed here, cannabinoids like fsCBD and bsCBD may cause drowsiness, changes in appetite or mood swings. Some individuals might experience digestive issues or headaches. The severity of side effects varies from person to person.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 0 to week 6, week 0 to week 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 0 to week 6, week 0 to week 12 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Cognition
Change in Neuropsychiatric Symptoms
Secondary study objectives
Change in Anxiety
Change in Biomarkers of Inflammation
Change in Biomarkers of Oxidative Stress
+4 more

Trial Design

3Treatment groups
Active Control
Placebo Group
Group I: Broad Spectrum CannabidiolActive Control1 Intervention
Broad Spectrum Cannabidiol (0.0% THC) Oral softgel capsule, 210mg/day
Group II: Full Spectrum CannabidiolActive Control1 Intervention
Full Spectrum Cannabidiol (\<0.3% THC) Oral softgel capsule, 210mg/day
Group III: Hemp Seed OilPlacebo Group1 Intervention
Placebo Oral softgel capsule, 210mg/day

Find a Location

Who is running the clinical trial?

University of Colorado, DenverLead Sponsor
1,810 Previous Clinical Trials
2,919,980 Total Patients Enrolled
Colorado State UniversityOTHER
132 Previous Clinical Trials
38,307 Total Patients Enrolled
Kent Hutchison, PhDPrincipal Investigatorkent.hutchison@cuanschutz.edu
2 Previous Clinical Trials
601 Total Patients Enrolled

Media Library

Cannabidiol (Cannabinoid) Clinical Trial Eligibility Overview. Trial Name: NCT05632627 — Phase 2
Traumatic Brain Injury Research Study Groups: Broad Spectrum Cannabidiol, Hemp Seed Oil, Full Spectrum Cannabidiol
Traumatic Brain Injury Clinical Trial 2023: Cannabidiol Highlights & Side Effects. Trial Name: NCT05632627 — Phase 2
Cannabidiol (Cannabinoid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05632627 — Phase 2
~41 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top